SURAMIN INHIBITS INTIMAL THICKENING FOLLOWING INTIMAL INJURY IN THE RABBIT AORTA IN-VIVO

被引:11
作者
ASADA, Y [1 ]
TSUNEYOSHI, A [1 ]
MARUTSUKA, K [1 ]
SUMIYOSHI, A [1 ]
机构
[1] MIYAZAKI MED COLL,DEPT PATHOL 1,MIYAZAKI 88916,JAPAN
关键词
SURAMIN; INTIMAL THICKENING; SMOOTH MUSCLE CELL PROLIFERATION; PLATELET FUNCTION;
D O I
10.1093/cvr/28.8.1166
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Proliferation of vascular smooth muscle cells is a major event in atherogenesis. Several growth factors have been well documented to control this proliferation. Inhibition by suramin of the binding of some growth factors to their receptors has recently been reported. The aim of this study was to examine the effects of this agent on neointimal thickening following intimal mechanical injury, as well as on platelet function. Methods: Intimal thickening was induced by indwelling of polyethylene tubing for 24 h in the rabbit aorta. Rabbits were killed 10 d after drawing out the tubing. Throughout the experiment, suramin (15 mg.kg(-1)) was injected intravenously every 24 h. Morphological and morphometrical studies were performed in the suramin treated group (n = 6) and in a control group (n = 6). Platelet-rich plasma was prepared from animals before and 3 h after injection of suramin. Platelet aggregation and ATP release induced by collagen were examined. Platelet adhesion on the de-endothelialised area of the rabbit aorta was also examined in the two groups. Results: The mean intimal thickening in the suramin treated group was significantly less than in the control group. Smooth muscle cell replication and cell density in the thickened intima of the suramin treated group were less than in control. Suramin did not affect collagen induced platelet aggregation, ATP release, or platelet adhesion. Conclusions: Suramin has an inhibitory effect on the neointimal thickening and intimal smooth muscle cell proliferation after intimal injury in the rabbit aorta, but has no effect on platelet function.
引用
收藏
页码:1166 / 1169
页数:4
相关论文
共 36 条
[1]   NUCLEOTIDE-SEQUENCE OF A BOVINE CLONE ENCODING THE ANGIOGENIC PROTEIN, BASIC FIBROBLAST GROWTH-FACTOR [J].
ABRAHAM, JA ;
MERGIA, A ;
WHANG, JL ;
TUMOLO, A ;
FRIEDMAN, J ;
HJERRILD, KA ;
GOSPODAROWICZ, D ;
FIDDES, JC .
SCIENCE, 1986, 233 (4763) :545-548
[2]   EFFICIENT REVERSION OF SIMIAN SARCOMA VIRUS-TRANSFORMATION AND INHIBITION OF GROWTH FACTOR-INDUCED MITOGENESIS BY SURAMIN [J].
BETSHOLTZ, C ;
JOHNSSON, A ;
HELDIN, CH ;
WESTERMARK, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (17) :6440-6444
[3]   AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL [J].
BORN, GVR .
NATURE, 1962, 194 (4832) :927-&
[4]   SURAMIN, AN EXPERIMENTAL CHEMOTHERAPEUTIC DRUG, ACTIVATES THE RECEPTOR FOR EPIDERMAL GROWTH-FACTOR AND PROMOTES GROWTH OF CERTAIN MALIGNANT-CELLS [J].
CARDINALI, M ;
SARTOR, O ;
ROBBINS, KC .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (04) :1242-1247
[5]  
CLOWES AW, 1991, J VASC SURG, V13, P885
[6]   SURAMIN INHIBITION OF GROWTH-FACTOR RECEPTOR-BINDING AND MITOGENICITY IN AKR-2B CELLS [J].
COFFEY, RJ ;
LEOF, EB ;
SHIPLEY, GD ;
MOSES, HL .
JOURNAL OF CELLULAR PHYSIOLOGY, 1987, 132 (01) :143-148
[7]  
COLLINS JM, 1986, J CLIN PHARMACOL, V26, P22
[8]  
COOPER M R, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P200
[9]  
EDWARDS G, 1986, ACTA PHARM TOXICO S5, V59, P222
[10]   SURAMIN, AN ACTIVE-DRUG FOR PROSTATE-CANCER - INTERIM OBSERVATIONS IN A PHASE-I TRIAL [J].
EISENBERGER, MA ;
REYNO, LM ;
JODRELL, DI ;
SINIBALDI, VJ ;
TKACZUK, KH ;
SRIDHARA, R ;
ZUHOWSKI, EG ;
LOWITT, MH ;
JACOBS, SC ;
EGORIN, MJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (08) :611-621